265 related articles for article (PubMed ID: 37443486)
1. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer.
Yu Z; Zhu Y; Ji J
Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
3. A mitochondrial function-related LncRNA signature predicts prognosis and immune microenvironment for breast cancer.
Wang Y; Gao S; Xu Y; Tang Z; Liu S
Sci Rep; 2023 Mar; 13(1):3918. PubMed ID: 36890266
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma.
Zeng C; Liu Y; He R; Lu X; Dai Y; Qi G; Liu J; Deng J; Lu W; Jin J; Liu Q
Front Genet; 2022; 13():935056. PubMed ID: 36092903
[No Abstract] [Full Text] [Related]
5. Identification of a pyroptosis-related prognostic signature in breast cancer.
Chen H; Luo H; Wang J; Li J; Jiang Y
BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644
[TBL] [Abstract][Full Text] [Related]
6. Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer.
Li C; Zhang Y
BMC Med Genomics; 2023 Jul; 16(1):158. PubMed ID: 37422644
[TBL] [Abstract][Full Text] [Related]
7. Identification of prognostic melatonin-related lncRNA signature in tumor immune microenvironment and drug resistance for breast cancer.
Gao SC; Wu MD; Zhang XX; Liu YF; Wang CL
Asian J Surg; 2023 Sep; 46(9):3529-3541. PubMed ID: 37330302
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer.
Cui H; Ren X; Dai L; Chang L; Liu D; Zhai Z; Kang H; Ma X
Front Immunol; 2023; 14():1145552. PubMed ID: 36969219
[TBL] [Abstract][Full Text] [Related]
9. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
10. A Novel Aging-Related Prognostic lncRNA Signature Correlated with Immune Cell Infiltration and Response to Immunotherapy in Breast Cancer.
Liu Z; Ren C; Cai J; Yin B; Yuan J; Ding R; Ming W; Sun Y; Li Y
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110517
[TBL] [Abstract][Full Text] [Related]
11. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model.
Lv Y; Bai Z; Wang X; Liu J; Li Y; Zhang X; Shan Y
Sci Rep; 2022 Nov; 12(1):20524. PubMed ID: 36443508
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of endocrine resistance-related and immune-related long non-coding RNA (lncRNA) signatures for predicting endocrinotherapy response and prognosis in breast cancer.
Yang M; Sun Y; Ji H; Zhang Q
Ann Transl Med; 2022 Dec; 10(24):1399. PubMed ID: 36660659
[TBL] [Abstract][Full Text] [Related]
15. Identification of Five Immune-Related lncRNAs Predicting Survival and Tumor Microenvironment Characteristics in Breast Cancer.
Xiao R; Yang M; Tan Y; Ding R; Li D
Comput Math Methods Med; 2021; 2021():6676692. PubMed ID: 33727952
[TBL] [Abstract][Full Text] [Related]
16. Development of the expression and prognostic significance of m
Xu G; Li C; Di Z; Yang Y; Liang L; Yuan Q; Yang Q; Dong X; Xu S; Wu G
Cancer Med; 2023 Mar; 12(6):7667-7681. PubMed ID: 36464884
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
18. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhong XY; Zeng N; Ma SY; He HD; Zhang ZB; Wang SG; Xia QD
Front Immunol; 2022; 13():908068. PubMed ID: 35898492
[TBL] [Abstract][Full Text] [Related]
19. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma.
Wang X; Pan Y; Ou Y; Duan T; Zou Y; Zhou X
World J Surg Oncol; 2022 May; 20(1):164. PubMed ID: 35606755
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
